Medically Unexplained Symptoms Clinical Trial
— SOMEX1Official title:
Randomized Controlled Trial of Internet-delivered Exposure-based Treatment vs. Standardized Education for Distress Related to Somatic Symptoms in Primary Care
Verified date | March 2024 |
Source | Region Stockholm |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The annual societal cost of medically unexplained symptoms in Sweden is approximately 40 billion SEK, i.e., similar to the annual cost of cancer. Prevalent chronic diseases like asthma and diabetes are also commonly associated with somatic symptoms that lead to significant distress and pervasive behavioral changes that result in functional impairment and place added strain on the health care system. Exposure-based treatment, where the patient willingly engages with stimuli that give rise to unwanted physical sensations or distress, has shown promise in reducing somatic symptom load and increasing quality of life in several conditions where patients commonly report substantial distress related to somatic symptoms, such as in asthma, musculoskeletal pain, and functional gastrointestinal syndromes. In routine care, however, access to such exposure-based treatment is limited. One reason for this is probably that there exists no flexible exposure-based treatment protocol that can be easily tailored to suit a wide spectrum of patient groups who suffer from distress related to recurrent somatic symptoms. In a recent single group feasibility trial (N=33) at Karolinska Institutet, Sweden, the investigators found that such a tailored exposure-based treatment delivered in an online text-based format can be acceptable, with high treatment adherence, adequate treatment satisfaction, large and lasting within-group improvement, and no serious adverse events. This is a randomized controlled trial (N=160) where the investigators aim to test if the same tailored internet-delivered exposure-based treatment is more efficacious than a standardized education control for adult patients with clinically significant distress related to somatic symptoms in a primary care setting. Primary outcome is change in self-rated somatic symptom burden as modelled using linear mixed models fitted on weekly Patient Health Questionnaire 15 sum scores over the treatment period. Long-term efficacy is assessed up to one year after treatment and cost-effectiveness is investigated based on the incremental cost-effectiveness ratio.
Status | Active, not recruiting |
Enrollment | 161 |
Est. completion date | January 31, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - (i) Either much bothered by at least one somatic symptom (2 points on at least one item of the PHQ-15) or at least a moderate overall somatic symptom burden (PHQ-15 sum =10), with (ii) recurrent distress related to somatic symptoms =4 months - Interested in completing an intense psychological treatment with the aim of reducing distress associated with physical symptoms - Adult (=18 years old) - Living in Stockholm County - Can read and write in Swedish - Complete baseline assessment Exclusion Criteria: - Symptoms best explained by, or clinical picture dominated by, severe health anxiety or a non-somatoform psychiatric disorder such as depression, panic disorder, primary insomnia, a chronic stress disorder, or an acute stress disorder - Severe psychiatric condition or suicidal ideation - Clear medical risk in taking part in exposure-based treatment (e.g., pregnancy) or somatic condition (e.g., recent cancer diagnosis), or treatment for somatic condition (e.g., recent chemotherapy), makes treatment unfeasible - Continuous psychotropic medication (antidepressants, anticonvulsants, mood-stabilizers, antipsychotics) not stable in past 4 weeks, or not expected to remain stable over the main phase of the trial - Severe alcohol or substance use disorder likely to interfere with treatment - Planned absence for more than 1 week during the intended main phase |
Country | Name | City | State |
---|---|---|---|
Sweden | Liljeholmen academic primary care clinic | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Region Stockholm | Karolinska Institutet |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient Health Questionnaire-15 (PHQ-15) | Theoretical range: 0-30. A higher score indicates a higher subjective somatic symptom burden. | Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (=45 days after treatment). Secondary analyses incorporate 6- and 12-months follow-up assessments. | |
Secondary | Somatic Symptom Disorder-B Criteria Scale (SSD-12) | Theoretical range: 0-48. A higher score indicates higher degree of preoccupation with symptoms. | Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (=45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments. | |
Secondary | Symptom Preoccupation Scale (preliminary scale) | Under development. A higher score indicates higher degree of preoccupation with symptoms. | Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (=45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments. | |
Secondary | GAD-7 | Theoretical range: 0-21. A higher score indicates more general anxiety. | Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (=45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments. | |
Secondary | Patient Health Questionnaire (PHQ-9) | Theoretical range: 0-27. A higher score indicates more symptoms of depression. | Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (=45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments. | |
Secondary | 12-item WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) | Theoretical range: 0-100. A higher score indicates more disability. | Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (=45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments. | |
Secondary | 14-item Health Anxiety Inventory (HAI-14) | Theoretical range: 0-42. A higher score indicates more health anxiety. | Screening only | |
Secondary | Alcohol Use Disorders Identification Test (AUDIT) | Theoretical range: 0-40. A higher score indicates more problematic alcohol use. | Screening only | |
Secondary | Drug Use Disorders Identification Test (DUDIT) | Theoretical range: 0-44. A higher score indicates more problematic substance use. | Screening only | |
Secondary | Credibility/Expectancy scale (C/E scale) | Theoretical range: 0-50. A higher score indicates higher credibility/expectancy. | Week 3 of main phase | |
Secondary | Working Alliance Inventory (WAI) | Theoretical range: 6-42. A higher score indicates better relationship with the therapist. | Week 3 of main phase | |
Secondary | Client Satisfaction Questionnaire (CSQ-8) | Theoretical range: 8-32. A higher score indicates higher satisfaction with treatment. | Primary endpoint assessment (=45 days after treatment) | |
Secondary | EuroQol 5D (EQ-5D) | Theoretical range: 0-1, i.e., scored as utility for the purpose of calculating quality-adjusted life years for health economic analysis. A higher utility score indicates a higher health-related quality of life. | Data from the baseline assessment, the primary endpoint, and the 6- and 12-month follow-up are used for health economic analysis focusing on the main phase. | |
Secondary | Trimbos Institute and Institute of Medical Technology Questionnaire for Costs Associated with Psychiatric Illness (TIC-P) | This instrument is scored in terms of resource use for the purpose of calculating societal costs for health economic analysis. | Data from the baseline assessment, the primary endpoint, and the 6- and 12-month follow-up are used for health economic analysis focusing on the main phase. | |
Secondary | Four questions corresponding to presumed components of subjective somatic symptom burden | These questions concern (1) somatic symptom severity, (2) somatic symptom frequency/duration, (3) distress related to somatic symptoms, and (4) the impact of somatic symptoms on disability. Answers are given on visual analogue scales. | Measured at screening, baseline assessment, and the primary endpoint | |
Secondary | Seven questions probing into basic emotions related to somatic symptoms | Answers are given on visual analogue scales. | Measured at screening, baseline assessment, and the primary endpoint |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05573919 -
VivAer: A Correlation Between Symptom Scores and Objective Findings
|
N/A | |
Completed |
NCT05611606 -
Welfare Benefits in Functional Somatic Disorders
|
||
Completed |
NCT05631860 -
Psychological Risk Factors for Functional Somatic Disorders
|
||
Not yet recruiting |
NCT04698824 -
Hypnosis in Internal Medecine
|
||
Recruiting |
NCT05121922 -
Sense of Coherence and Empowerment at Patients With MUPS
|
N/A | |
Completed |
NCT04277715 -
Parent Training for Youth With Chronic Symptoms
|
N/A | |
Completed |
NCT01935258 -
Psychosomatic Therapy, Feasibility and Cost Analysis
|
N/A |